Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 17:15:1553505.
doi: 10.3389/fonc.2025.1553505. eCollection 2025.

PSMA-targeted PET imaging for brain metastases from non-prostatic solid tumors: a systematic review

Sara Dall' Armellina  1 , Gayane Aghakhanyan  2 , Alessio Rizzo  3 , Salvatore C Fanni  4 , Giacomo Aringhieri  4 , Lorenzo Faggioni  4 , Dania Cioni  4 , Emanuele Neri  4 , Duccio Volterrani  2 , Silvia Morbelli  5   6
Affiliations

PSMA-targeted PET imaging for brain metastases from non-prostatic solid tumors: a systematic review

Sara Dall' Armellina et al. Front Oncol. .

Abstract

Introduction: Prostate-Specific Membrane Antigen (PSMA) is a transmembrane glycoprotein initially identified in prostate cancer (PCa) but also expressed in the neovasculature of various solid tumors. Recently, PSMA PET has emerged as a promising tool for detecting brain metastases (BMs) from non-prostatic cancers, offering diagnostic capabilities in addition to conventional imaging. This systematic review evaluates the role of PSMA-targeted radiopharmaceuticals in imaging BMs, highlighting their comparative diagnostic performance and exploring their potential for theranostic applications.

Methods: A systematic review of the literature was conducted following PRISMA guidelines. Studies evaluating the diagnostic accuracy of PSMA PET imaging in identifying brain metastases (BMs) from non-prostatic solid tumors were included. Both full research articles and case reports were considered to capture the breadth of current evidence. The methodological quality of the included studies was assessed using the QUADAS-2 tool, and data were synthesized qualitatively.

Results: The review includes 23 studies reporting on 77 BMs from diverse primary malignancies, including lung, breast, salivary gland, thyroid, kidney, and melanoma. PSMA PET demonstrated high tumor-to-background ratios (TBR), enabling superior detection of BMs compared to conventional imaging modalities such as contrast-enhanced MRI and [18F]FDG PET. In post-radiotherapy cases, PSMA PET effectively differentiated radionecrosis from tumor recurrence. Moreover, PSMA PET demonstrated superior sensitivity in detecting thyroid metastases compared to traditional scintigraphy methods, highlighting its potential in cases where standard techniques yield inconclusive results.

Conclusions: PSMA PET imaging shows significant promise in improving the diagnosis and management of BMs from non-prostatic cancers. While its theranostic applications remain underexplored, initial findings suggest promising avenues for integrating PSMA PET into personalized neuro-oncology care. Future studies should focus on standardizing imaging protocols, exploring PSMA PET utility in diverse tumor subtypes, and validating its role in clinical decision-making to maximize its impact on patient outcomes.

Keywords: PSMA PET; Positron-Emission Tomography; brain metastases; neuro-oncology; non-prostatic solid tumors; theranostics.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
PRISMA flowchart of research strategy and study selection.
Figure 2
Figure 2
Graphical display for QUADAS-2 results.
See this image and copyright information in PMC

References

    1. Troyer JK, Beckett ML, Wright GL. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer. (1995) 62:552–8. doi: 10.1002/ijc.2910620511 - DOI - PubMed
    1. Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. . EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer—2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urology. (2024) 86:148–63. doi: 10.1016/j.eururo.2024.03.027 - DOI - PubMed
    1. Bauckneht M, Checcucci E, Cisero E, Rizzo A, Racca M, De Cillis S, et al. . The prognostic role of next-generation imaging-driven upstaging in newly diagnosed prostate cancer patients. Eur J Nucl Med Mol Imaging. (2024) 51:864–70. doi: 10.1007/s00259-023-06490-z - DOI - PubMed
    1. Israeli RS, Powell CT, Fair WR, Heston WD. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. (1993) 53:227–30. - PubMed
    1. Chang SS, O’Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res. (1999) 5:2674–81. - PubMed

Publication types

LinkOut - more resources